Latest Insights - page 8 | BiopharmaTrend

In an AI-Enabled ALS Study, Digital Twins Support Gene-Delivered Antibody Trial

In a collaboration that embeds AI directly into trial design and analysis to reduce statistical and operational risk, Unlearn will deploy patient-level AI-generated digital twins in VectorY Therapeutics’ PIONEER-ALS Phase …

Continue ›››

New-Modality Drugs Behind Today’s Big Headlines

How advanced therapeutics are solving “undruggable” biology and creating industry’s most valuable assets. A lot has been happening lately across biopharma spanning massive deals and landmark approvals. Madrigal Pharmaceuticals has …

Continue ›››

Five Women Shaping the AI–Life Science Stack

February 11 marks the UN-designated International Day of Women and Girls in Science, established by the General Assembly in December 2015 to recognize the contributions of women in scientific fields …

Continue ›››

Isomorphic Labs Presents an AI Drug Design Engine That Goes Beyond AlphaFold 3

On the heels of Johnson & Johnson multi-modality drug discovery collaboration last month, Isomorphic Labs has now published benchmark results for its unified AI drug design engine, the Isomorphic Labs …

Continue ›››

Takeda Signs $1.7B AI-Enabled Small Molecule Discovery Deal with Iambic

Takeda has entered a multi-year agreement with Iambic Therapeutics to deploy Iambic’s AI-driven small molecule discovery platform across oncology, gastrointestinal, and inflammation programs. The deal includes access to Iambic’s software …

Continue ›››

Big Pharma’s China Deal Wave & 12 Companies on Our Radar

A snap look at some of the deal dynamics and company platforms pulling global pharma toward China. In late January, AstraZeneca announced a $15B investment in China through 2030, expanding …

Continue ›››

How 2026 Started: First-Weeks Readout on AI, Pharma, & Policy

Early-year overview spanning virtual cell modeling, AI workflow plumbing in R&D and healthcare, obesity-driven capital and licensing, patent-cliff positioning, and FDA/EU policy signals. The year opened hot, with the first …

Continue ›››

Flagship’s Generate Biomedicines Eyes IPO Amid Reopening Biotech Market Window

Generate Biomedicines, a Flagship Pioneering-founded antibody platform company, has filed for an initial public offering as part of a growing wave of biotech listings in early 2026. The company has …

Continue ›››

Phylo, an Agentic AI Lab, Launches with $13.5M Seed Round, Introduces Biomni Lab

Phylo, a Stanford spin-out, has just launched as an applied lab focused on agentic AI for biomedical research. Alongside the launch, the team announced Biomni Lab, reportedly the first “Integrated …

Continue ›››

Inductive Bio Wins OpenADMET Blind Challenge With Machine Learning Models

Inductive Bio placed first in the OpenADMET-ExpansionRx blind challenge with its Beacon models, a large-scale industry competition for ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) property prediction, surpassing over 370 …

Continue ›››

A New Combination Strategy Shows Up to 31.3% Weight Loss in Preclinical Study

The modern obesity drug race has been defined by one word: incretins. Blockbuster GLP-1 receptor agonists from companies like Novo Nordisk and Eli Lilly have reshaped both waistlines and Wall …

Continue ›››

Anthropic, HHMI, and Allen Institute Launch Claude-Integrated AI Collaborations for Life Science Research

Anthropic has formalized partnerships with the Howard Hughes Medical Institute (HHMI) and the Allen Institute to integrate its Claude model into core scientific workflows, targeting persistent bottlenecks in experimental interpretation …

Continue ›››